Thursday, July 3, 2025 7/3/2025

AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline

Award Number: R01AG051658
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2015
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline - Project Summary/Abstract Delirium (acute confusion), is a major complication of surgery in older patients, strongly associated with long term cognitive decline (LTCD) and Alzheimer's Disease and Related Dementias (AD/ADRD). Prevention of postoperative delirium and its long-term complications would be advanced if we could better identify at-risk patients preoperatively, and if targeted pathophysiologically-based interventions could be implemented. To address these gaps, we conducted the NIA-funded “Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics” R01 project and program project that funded the SAGES (Successful Aging after Elective Surgery) I and II studies. We identified and validated pre- and post-operative delirium protein signatures, demonstrating that pro-inflammatory proteins, acute phase reactants, angiogenic, and neuronal injury markers are elevated in patients who develop delirium. A model of delirium pathophysiology has emerged that stipulates a systemic pre-inflammatory state predisposes to a hyperactive inflammatory response from major surgery, leading to delirium, and potentially LTCD and AD/ADRD in individuals with a vulnerable brain. While intriguing, this model does not fully address the complex inter-relationship between delirium and AD/ADRD. For our R01 renewal, we hypothesize that AD/ADRD susceptibility and accelerated biological aging are key predisposing factors for delirium and delirium with LTCD, which in turn may increase risk for AD/ADRD. SomaScan-based plasma proteomic signatures predicting AD/ADRD up to 20 years before onset, and proteomic aging clocks, panels of plasma proteins measuring biological aging relative to chronological age, have been developed and extensively validated in large cohorts. We will use the state-of-the-art SomaScan proteomics platform that measures 7,000 proteins to test our hypotheses that AD/ADRD proteomic signatures (Aim 1) and proteomic aging clocks (Aim 2) predict postoperative delirium and delirium with LTCD. We will capitalize upon the pre- and post-operative banked specimens from SAGES I (N=560) with continuous follow-up to 72 months after major scheduled surgery, and a second, recently accrued independent cohort, SAGES II (N=400), with similar characteristics and follow-up to 18 months. We will combine proteins from the AD/ADRD and aging proteomic signatures, along with additional proteins from the 7,000 protein SomaScan covering many biological pathways, for a deep etiopathological characterization of the plasma proteome for delirium and delirium with LTCD in SAGES I (Aim 3) and independent validation of the proteomic signature for delirium using both SomaScan and ELISA with plasma from SAGES II (Aim 4). Our R01 renewal Aims will provide new insights into molecular mechanisms underlying delirium pathogenesis and its association with AD/ADRD and biological aging. This project holds great promise to develop accurate blood-based biomarkers for preoperative delirium risk prediction, postoperative prognostication of LTCD following delirium, and to lay the groundwork for targeted interventions to improve outcomes of older adults at risk of delirium.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $758,879 )
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	001	7	11/26/2024	NON-COMPETING CONTINUATION	$763,807
2025	2018	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	3	10/1/2024	SUPPLEMENT FOR EXPANSION	-$4,928
														Subtotal = $758,879

Issue Date FY: 2024 ( Subtotal = $870,666 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	001	6	5/13/2024	NON-COMPETING CONTINUATION	$87,066
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	6	12/21/2023	NON-COMPETING CONTINUATION	$783,600
														Subtotal = $870,666

Issue Date FY: 2023 ( Subtotal = $874,146 )
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	001	5	11/22/2022	COMPETING CONTINUATION	$874,146
2023	2019	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	4	11/10/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $874,146

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	4	1/5/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	4	2/1/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $485,512 )
2019	2019	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	4	12/24/2018	NON-COMPETING CONTINUATION	$485,512
														Subtotal = $485,512

Issue Date FY: 2018 ( Subtotal = $788,425 )
2018	2018	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	3	12/15/2017	NON-COMPETING CONTINUATION	$560,082
2018	2018	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	002	3	9/11/2018	SUPPLEMENT FOR EXPANSION	$166,112
2018	2018	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	001	3	4/25/2018	NON-COMPETING CONTINUATION	$62,231
														Subtotal = $788,425

Issue Date FY: 2017 ( Subtotal = $602,453 )
2017	2017	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	001	2	6/14/2017	NON-COMPETING CONTINUATION	$60,245
2017	2017	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	2	12/14/2016	NON-COMPETING CONTINUATION	$542,208
														Subtotal = $602,453

Issue Date FY: 2016 ( Subtotal = $630,249 )
2016	2016	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	1	1/11/2016	NEW	$630,249
2016	2016	BETH ISRAEL HOSPITAL	330 BROOKLINE AVENUE	BOSTON	MA	02115	SUFFOLK	USA	Aging Research	001	1	3/17/2016	NEW	$0
														Subtotal = $630,249

Grand Total All Awards = $5,010,330

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline

Award Number: R01AG051658

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2015

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer